Aprotinin is not discussed because the drug was removed from the market on the assumption that it raises mortality, as reported in a Canadian Trial in 2007 42.
No se considera la aprotinina, por estar retirada del mercado ante el supuesto aumento de mortalidad que provoca, reportado en un estudio canadiense de 2007 42.